Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Vesicular Trafficking Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAB7B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAB7B Recombinant Protein (WT / Mutant) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for nucleotide binding and exchange assays. |
View RAB7B Products |
| Gene Delivery | RAB7B Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to study vesicular trafficking and TLR4 downregulation. |
View RAB7B Products |
| Benchmark Ab | Anti-RAB7B Recombinant Antibody Recombinant positive control for Western Blot, Immunofluorescence, and IP validation. |
View RAB7B Products |
| Validator | RAB7B siRNA Set For specific knockdown verification in functional phenotypic assays. |
View RAB7B Products |
| Related Target A | TLR4 RAB7B acts as a negative regulator of TLR4 signaling by promoting its lysosomal degradation. Critical for inflammation studies. |
View TLR4 Products |
| Related Target B | RAB7A Closest structural homolog. Essential counter-screening target to ensure drug selectivity and avoid systemic autophagy toxicity. |
View RAB7A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homolog Counter-Screening (RAB7A vs. RAB7B) | High-purity human RAB7A and RAB7B ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Nucleotide-Binding State Verification (GTP/GDP) | Biophysically intact recombinant proteins optimized for SPR/MST binding affinity assays. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives in Phenotypic Screening | Validated siRNA pools included for target-specific knockdown control. |
Live RAB7B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAB7B therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory agents to intracellular trafficking modulators. As first-generation small-molecule GTPase regulators reach the clinic, the next wave of R&D is targeting downstream lysosomal degradation pathways and TLR4-mediated auto-inflammatory disease models.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (GTPase Inhibitors) | Academic Institutes, Biotech Startups | Autoimmune Diseases, Sepsis | Selectivity Assay (Need Mutant vs WT Proteins to verify active site binding) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Chronic Inflammatory Disorders | Ubiquitination & Degradation Assay (Need high-purity recombinant RAB7B as substrate) |
| Gene Therapy / RNAi | RNA Therapeutics Companies | Hyper-inflammatory Syndromes | Target Knockdown Validation (Need Lentivirus and siRNA validation tools) |